In this context, a combination of AD biomarkers in cerebrospinal fluid (Aβ42, tau, and phospho-tau), non-invasive neuroimaging, and genetic risk factors have been investigated with promising but also conflicting data (for review, see Khan, 2018). The gene discussed is MAPT; the disease is Alzheimer disease.